TOPIMIRATE prophylaxis was linked to reduced cluster headache pain and disability in adults across this prospective cohort.
Topiramate for Cluster Headache Prophylaxis
Topiramate may offer a useful prophylactic option for adults with cluster headache, according to a prospective observational cohort study evaluating its use as monotherapy in both episodic and chronic disease. The study was designed to assess not only symptom control, but also headache related disability and quality of life domains that have been less thoroughly explored in previous reports.
Researchers followed 51 adults with cluster headache between October 2023 and December 2024. Patients with other headache types, prior anticonvulsant use, malignancy, pregnancy, or lactation were excluded. Participants received topiramate beginning at 25 mg/day, with weekly titration up to 100 mg. Treatment response was monitored using Visual Analog Scale scores and HIT-6 scores on a weekly basis.
Pain Severity and Disability Improved Over Time
The cohort was predominantly male, accounting for 64.7% of patients, with a mean age of 38.6 years. Across the full study population, both pain severity and headache related disability improved significantly over time. Reductions in Visual Analog Scale and HIT-6 scores were seen regardless of whether topiramate was used as a first line option or introduced at follow up, suggesting a broadly consistent treatment effect within the observational cohort.
Differences did emerge between episodic and chronic cluster headache. Patients with chronic disease entered the study with higher HIT-6 scores, indicating a greater baseline burden. Although they also improved during treatment, their progress was slower than that observed in episodic cases. This finding may be clinically relevant when discussing expectations for response and follow up in more persistent disease.
Tolerability Supports Further Evaluation
Topiramate was generally well tolerated. Somnolence was the most commonly reported adverse effect, occurring in 19.6% of patients. Importantly, no patients discontinued therapy because of side effects. Taken together, the findings suggest that topiramate monotherapy may represent a potential first line or alternative prophylactic strategy in selected patients with cluster headache, particularly where treatment options are limited or where avoiding polypharmacy is a priority.
While the authors note the observational nature of the study, the consistent improvement in pain and disability supports further evaluation of topiramate in cluster headache prophylaxis.
Reference
Shafiyev J et al. The evaluation of topiramate as a first-line medication for cluster headache prophylaxis: a prospective observational cohort study. Clin Neuropharmacol. 2026;doi:10.1097/WNF.0000000000000678.
